Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in China: A Non-interventional Study "XASSURE"


Phase Results N/A

Eligibility Criteria

Inclusion Criteria

- Female and male patients ≥ 18 years of age diagnosed with non-valvular atrial fibrillation
- Patients for whom the decision to initiate treatment with rivaroxaban to prevent stroke or non-CNS systemic embolism was made as per investigator's routine treatment practice
Exclusion Criteria: